miRNAs are an important class of small non-coding RNAs, playing a versatile role in the 98 gene regulation at the post -transcriptional level [1] [2] [3] [4] [5] . These molecules have proven to be 99 involved in vital cellular functions, such as development, differentiation and metabolism [6] [7] [8] . 100
In recent years there has been increased focus on the role of miRNAs in cancer [9] , and the 101 implementation of next generation sequencing (NGS) has lead to the identification of multiple 102 novel miRNAs as well as linked individual miRNA expression and combined signatures to 103 tumor characteristics [10] . Currently there are 2656 distinct human miRNAs identified in the 142
Materials and Methods

144
Patients 145 146
In the present work we have analyzed biopsy material from two breast cancer studies. 147 148
1) In the first study, incisional biopsies were collected before chemotherapy from 223 149 patients with locally advanced breast cancer in a prospective study designed to identify the 150 response to epirubicin (n = 109) and paclitaxel (n = 114) monotherapy. Primary response to 151 therapy as well as long-term follow up (>10 years or death) was recorded for all patients. 152 This cohort has been described in detail previously [26] . 153 154
2) In the second study, tumor breast tissue and normal breast tissue from tumor bearing and 155 non-tumor bearing quadrants were collected from 46 anonymous breast cancer patients 156
undergoing mastectomy, with the purpose of determining tissue estrogens. This cohort is 157 described in detail in [27] . 158 159
Using NGS, we analyzed miRNA expression in 50 patients from study 1). Next, candidate 160 miRNAs were quantified using qPCR in all 223 patients from study 1), as well as 13 161 randomly selected patients from study 2), where RNA was available from tumor tissue and 162 matching normal breast tissue (7 ER-positive and 6 ER-negative tumors). In addition, mRNA 163 expression array data was available for 203 out of the 223 patients in study 1). 164 165
All patients provided written informed consent, and the studies conducted in accordance to 166 national laws, regulation and ethical permissions. 167 168
Tissue Sampling and RNA extraction 169 170
Tissue samples were snap-frozen in liquid nitrogen in the operating theatre and stored in 171 liquid nitrogen until further processing. Total RNA was extracted from the biopsies using 172 miRvanaTM kit (ThermoFisher), according to the manufacturer's instructions. RNA End products from custom miRNA specific qPCR were cloned into pCR 2.1 TOPO-TA vector 210 (Life Technologies) by TOPO-TA cloning according to the manufacturer's instructions. The 211 generated plasmids were amplified by transformation and cultivation of E. coli TOP10 cells 212
(Life Technologies). The plasmids were then isolated using the Qiagen miniprep kit 213
according to the manufacturer's instructions.
214
Sequencing was performed using the BigDye v.1.3 system (Applied Biosystems) and 215 the primers following thermocycling conditions as previously described [30] . Capillary 216 electrophoresis and data collection were performed on an automated capillary sequencer 217 (ABI3700). 218 219 220
Target prediction and pathway analysis 221 222
Target prediction was performed using the offline algorithm miRanda [31, 32] The miRDB is an online database of animal miRNA targets, which uses SVM 229
(Support Vector Machine) machine-learning algorithm trained with miRNA-target binding data 230 from already known and validated miRNA-mRNA interactions [33, 37] . 231
TargetScanHuman Custom predicts biological miRNA targets by searching for match 232
for the seed region of the given miRNA that is present in the conserved 8-mer and 7-mer 233 sites [34] . It also identifies sites with conserved 3' pairing from the mismatches in the seed 234 region [38, 39] . 235
An in-house pan-cancer panel of 283 tumor suppressor genes was used to filter 236 target genes of interest. The panel was generated based on the tumor suppressors within the Table 1 ). 239
Further, we used GATHER, a functional gene enrichment tool, which integrates 240 various available biological databases to find functional molecular patterns, in order to find 241 biological context from the target gene list [41] . With the help of GATHER, we did KEGG 242 pathway [42] , and GO (gene ontology) enrichment analyses for the common genes predicted 243 by all three prediction algorithms. 244 245 246 mRNA expression 247 248
In the interest of validating miRNA targets, we analyzed inverse correlations between miRNA 249 expression and mRNA levels. mRNA expression levels were extracted from microarray 250 analyses performed on a Human HT-12-v4 BeadChip (Illumina) after labeling (Ambion; Aros 251
Applied Biotechnology). Illumina BeadArray Reader (Illumina) and the Bead Scan Software 252
(Illumina) were used to scan BeadChips. Expression signals from the beads were normalized 253 and further processed as previously described [43] . We re-annotated the data set using 254
illuminaHumanv4.db from AnnotationDbi package, built under Bioconductor 3.3 in R [44], to 255 select only probes with "Perfect" annotation [45] . The probes represented 21043 identified 256
and unique genes (13340 represented by single probe and 7703 represented by multiple 257 probes). In the cases of multiple probes targeting the same gene, we calculated fold 258 difference for these probes. This was done to avoid losing potentially relevant biological 259
information if expression of one probe was significantly higher that expression of another. 260
However, for no genes did we find a fold difference >2 fold. Therefore, the mean expression 261
for each such gene, was calculated based on the values form each probe, weighted 262
according to the number of beads per probe. 
Results
287
Novel miRNA prediction 288 289
In order to identify novel miRNAs, 50 patients with locally advanced breast cancer (from 290 study 1, see materials and methods) were subject to global miRNA-sequencing using 291 massive parallel sequencing. On average, the dataset resulted in 3 million reads per sample. 292
Using the miRNA identifier module in miRDeep2, we detected 10 novel miRNAs (Table 1) . 293
Eight out of these 10 miRNAs were detected in a single sample only, while two were 294 expressed in two or more patients and therefore regarded as the most reliable predictions. 295
These two miRNAs, here temporarily named hsa-miR-nov3 and hsa-miR-nov7, were found in 296 tumor samples from 2 and from 6 patients, respectively. For both of these novel miRNAs, we 297
identified precursor structures with not more than one or two mismatches in the stem region, 298
as well as the presence of mature miRNA sequences (Fig 1; Supporting Fig 1) . Therefore, 299
we selected these two miRNAs for further analyses. Notably, while this work was conducted, 300
hsa-miR-nov7 was identified by another team in lymphomas, and reported as miR-10393-3p 301
[46]. 302 303 304 Next, we aimed to validate our in-silico predictions and confirm that the sequences from 318
which we identified hsa-miR-nov3 and hsa-miR-nov7 represented bona-fide novel miRNAs 319 expressed in the patients. Utilizing total RNA from the patients found to express the two 320 predicted novel miRNAs, we performed global poly-adenylation and cDNA synthesis followed 321
by miRNA-specific qPCR amplification. For both miRNAs we observed positive qPCR 322
reactions. Further, end products of the qPCRs were then ligated into carrier-plasmids and 323
sequenced. We confirmed the resulting plasmids to contain the predicted miRNA sequences. 324
Further, in both cases, the sequences were flanked by a poly A tail, confirming that the 325 original molecules used as input in the poly-adenylation were present as short 22nt RNAs 326 (Fig 2) . miRNA-sequence region (reverse complementary), followed by the Adenine homopolymer 332
indicating in vitro adenylation at the expected site. 333 334 335 336
Overexpression of hsa-miR-nov7 and hsa-miR-nov3 in breast cancer 337 338
Given that the sensitivity for the novel miRNAs was better in the qPCR than in the miRNA 339 massive parallel sequencing (MPS) analysis, we aimed to assess whether the miRNAs were 340 expressed in a limited number of breast cancer patients only (as indicated by their detection 341
in 2 and 6 out of 50 patients in the MPS analysis), or if they were detectable in a higher 342 fraction of patients, when applying a more sensitive detection method. We therefore 343 performed qPCR to quantify the expression levels of hsa-miR-nov7 and hsa-miR-nov3 in 344
tumor tissue across the entire cohort of patients from study 1 (n = 223). With this method, we 345
detected hsa-miR-nov7 and hsa-miR-nov3 in 206 and 214 samples out of total 223 samples 346
respectively, albeit at variable levels (Fig 3) . 347
Interestingly, while no difference in the expression levels of hsa-miR-nov7 was 348 observed between breast cancer subgroups, we found a significant difference in the 349 expression levels of has-miR-nov3 related to estrogen receptor status. Thus, the expression 350 levels of has-miR-nov3 were higher in ER-positive as compared to ER-negative tumors 351 (p=0.037; Fig 4A) . Further, assessing the expression levels of the two miRNAs in mRNA-352 based subclasses of breast cancer according to the Perou classification [47] , comparing all 353 five classes, we observed a significant difference between the subtypes with respect to miR-354 nov3 expression (p=0.041; Kruskal-Wallis test; Fig 4c) . We found hsa-miR-nov3 levels to be 355 lower in HER2 like (p = 0.009; Mann-Whitney test) and basal-like (p = 0.04; Mann-Whitney) 356
tumors as compared to tumors of the other classes.
357
Following the finding that the two miRNAs were detectable in more than 90 percent of 358 patients, in order to assess whether the expression of these miRNAs were tumor specific we 359 compared the levels of hsa-miR-nov7 and hsa-miR-nov3 expression in breast cancer tissue 360 versus normal breast tissue. For this purpose, we randomly selected 13 patients from a study 361
where samples of breast tumor tissue and matching normal tissue from a non-tumor bearing 362 quadrant of the same breast were available (study 2, see materials and methods) [27] . We 363 detected expression of the novel miRNAs in both tumor-and normal tissue samples for all 13 364
patients. Notably, we found hsa-miR-nov3 expression to be elevated in tumor compared to 365 normal tissue in 10 out of the 13 patients (p=0.009; Wilcoxon test; Fig 5A) . Similar findings 366
were observed for hsa-miR-nov7 with elevated expression in 10 out of 13 tumors (Wilcoxon: 367 p = 0.016; Fig 5B) . The level of overexpression (i.e. the ratio of expression levels in tumor 368 versus normal tissue) for the two miRNAs did not correlate to each other (p>0.2; Spearman). 369
Notably, overexpression of hsa-miR-nov7 in tumor versus normal tissue was 370 observed predominantly in ER-positive tumors (overexpression in 7 out of 7 ER-positive 371 tumors, contrasting 3 out of 6 ER-negative tumors; p=0.070; Fischer exact test). Based on our finding of both novel miRNAs to be overexpressed in breast cancer, we next 389 aimed to elucidate the functional roles for hsa-miR-nov7 and hsa-miR-nov3 by identifying 390 potential targets. We performed in silico target predictions using three different algorithms -391 miRanda, miRDB and TargetScanHumanCustom. miRanda, whch predicts possible targets 392 from human transcripts in general, predicted 9200 and 12315 target genes for hsa-miR-nov7 393
and hsa-miR-nov3, respectively. miRDB, which contains curated and possible miRNA 394 targets, predicted 570 and 530 target genes each for hsa-miR-nov7 and hsa-miR-nov3, 395
respectively, while TargetScanHuman custom predicted 633 target genes for hsa-miR-nov7, 396
and 282 target genes for hsa-miR-nov3. For increased stringency in our predictions, we 397 restricted the potential targets to the ones called by all three algorithms (Fig 6) . This left a 398 total of 97 and 180 potential targets for hsa-miR-nov3 and hsa-mir-nov7, respectively. 399
The two lists of 97 and 180 predicted gene targets were then used for KEGG pathway 400 analysis and GO enrichment analysis using GATHER. The top 10 KEGG pathways and GO 401
terms for each microRNAs are listed in In order to further substantiate these in-silico predictions, we performed a complete 407
Spearman correlation analysis between the expression levels of hsa-miR-nov7 and hsa-miR-408 nov3 and mRNA expression array data available for 203 out of the 233 patients in study 1.
409
Assuming the miRNAs, in general, to execute their function by suppressing gene expression 410 (mRNA degradation), we restricted the analysis to genes which were negatively correlated to 411 expression of the miRNAs. The top ranking negatively correlated genes are listed in Table 3 . 412
Notably, the only genes with Rho-values < -0.2 were RMND5A for hsa-miR-nov3 and GLUD1 413
and SASH1 for hsa-miR-nov7. Given that the two novel miRNAs were overexpressed in 414 breast cancer tissue, we went on to restrict the correlation analysis to an in-house list of 283-415 tumor suppressor genes previously described (Supporting Table 2 ). Among these tumor 416 suppressors, we found 115 to be negatively correlated to hsa-miR-nov7 and 119 to hsa-miR-417
nov3. Assessing the intersection between these negatively correlated tumor suppressor 418 genes and the predicted targets, we obtained a list of one gene for hsa-miR-nov3 (ATRX) 419
and three genes for hsa-miR-nov7 (APC, SFRP2 and CDH11), but the correlations were 420
non-significant in all 4 cases ( Fig 7) . 421
In order to get a broader overview of potential biological function, we selected the 422 100 gene transcripts with the strongest positive and the top 100 gene transcripts with the 423 strongest negative correlation to the two miRNAs (independent of previous target-424 predictions) and performed gene ontology analyses. We detected no cancer related 425 pathways or cellular functions to be significantly associated with hsa-miR-nov7 (Supporting 426  Table S3 ). However, for hsa-miR-nov3, KEGG analysis of the negatively correlated genes 427
revealed associations to Hepatorcellular carcinoma as well as several pathways related to 428 drug metabolism ( Supporting Table S4 ). Since both hsa-miR-nov7 and hsa-miR-nov3 were overexpressed in the tumor tissue of 508 breast cancer patients, we assessed whether any of the two novel miRNAs were associated 509
to clinical outcomes in study 1 (223 breast cancer patients). Given that these patients were 510
enrolled in a prospective study specifically designed to assess response to primary 511 chemotherapy administered as epirubicin or paclitaxel monotherapy in a neoadjuvant setting 512 [26, 48] , we assessed the association of hsa-miR-nov7 and hsa-miR-nov3 levels with primary 513 therapy response and with long term survival (10-years). 514
We found no association between any of the two novel miRNAs and primary 515 response to either epirubicin or paclitaxel (data not shown). Regarding survival, we observed 516 a weak association between high levels of hsa-miR-nov7 and poor survival in the paclitaxel 517 treated arm of the study, with the strongest associations observed for relapse free survival, 518
however, none of these associations reached statistical significance (Fig 8) . No effect was 519 observed in the epirubicin treated arm. Further, for hsa-miR-nov3, no significant correlation 520 to outcome was recorded. 521
Given the skewed expression levels between breast cancer subtypes for hsa-miR-522 nov3, we performed survival analyses stratified for ER-status and subtypes. These analyses 523 revealed no significant associations to survival (data not shown). We investigated whether we could detect novel, previously undescribed miRNAs and, if so, 537
address their potential association to other defined biological parameters and to outcome in a 538 cohort of locally advanced breast cancer. We successfully predicted 10 new miRNAs, out of 539 which 2 were deemed reliable because of their detected presence in more than one patient. 540
Although these two novel miRNAs (preliminary termed hsa-miR-nov7 and hsa-miR-nov3) 541
were only predicted from 8 samples among the 50 initially sequenced biopsies, we found 542 them to be expressed in all patients by highly sensitive qPCR at varying levels. In addition to 543 our in vitro validations, the qPCR detection validated the initial NGS based analysis, 544 detecting these two miRNAs. 545
Since expression of the two miRNAs was confirmed in breast tumor tissue from the 546 majority of patients analyzed, we went on to assess the relative expression levels in tumor 547 versus matched normal breast tissue, collected from a non-tumor bearing quadrant. Our 548
finding that both novel miRNAs had higher expression levels in tumor than in normal tissue 549
indicates a potential functional role in breast cancer. However, although being 550 overexpressed, the biological role of these two miRNAs in cancer should be interpreted with 551
caution. The expression levels are very low, and it is therefore uncertain whether they will 552
have a major impact on cellular functions. However, when assessing the potential functional 553 roles of these microRNAs by in silico prediction of targets followed by validation using 554 correlation to mRNA-array data, the KEGG and GO annotations for these targets revealed 555 cellular functions of potential importance in development and progression of cancer. As such, 556
our present findings may warrant further investigations into the functions of the two miRNAs. 557
Notably, regarding hsa-miR-nov3, it was of particular interest that this miRNA was 558 significantly higher expressed in ER-positive as compared to ER-negative breast cancers. 559
Accordingly, we found relatively high expression levels of hsa-miR-nov3 in tumors of the 560 luminal and normal-like subtypes, contrasting low expression levels in basal-like and her2-561 like tumors [49, 50] . This finding may indicate a potential role for hsa-miR-nov3 restricted to 562 ER-positive tumors. 563
Regarding potential specific targets, we narrowed these down by first assessing the 564 intersect of three different target prediction algorithms, and then the intersect of this result 565 with a predefined list of tumor suppressors. Although none of the remaining genes after this 566
filtering had a statistically significant inverse correlation with the miRNAs, we identified some 567 potentially interesting connections: For hsa-miR-nov3, we propose ATRX as a target. This is 568 a gene in the SWI/SNF family, involved in chromatin remodelling, and it has previously been 569 found subject to loss of heterozygosity (LOH) in breast cancer [51] . Importantly, we recently 570
reported mutations in the SWI/SNF family genes to be enriched in relapsed breast cancer as 571 compared to primary cancers [52] . Thus, this supports the hypothesis of a breast cancer 572
promoting function for hsa-miR-nov3. For hsa-miR-nov7, we propose APC, SFRP2, and 573 CDH11 as potential targets. Interestingly, the two former are involved in regulation of the 574
Wnt-signalling pathway [53-55] and both have previously been reported as targets for several 575 miRNAs in breast cancer [56] [57] [58] . Taken together, this may imply a role for hsa-miR-nov7 in 576
Wnt signaling. Notably, during our work with the present project, hsa-miR-nov7, was 577 identified by Lim and colleagues and coined miR-10393-3p [46] . They found this miRNA to 578 target genes involved in chromatin modifications associated with pathogenesis of Diffuse 579 large B-cell lymphoma (DLBCL). While this differs from our present finding, it may likely be 580 explained by tissue specific effects of the miRNA. 581
Regarding any predictive or prognostic role for the two investigated miRNAs, we 582 found no significant impact on survival. While we recorded a non-significant trend towards an 583 association between miRnov7 expression and overall survival in the paclitaxel arm, further 584 studies on larger patient cohorts are warranted to clarify this issue. Alternatively, the miRNAs 585 could play a role in tumorigenesis but not later tumor progression. As such, the observed 586 overexpression in tumor tissue compared to normal breast tissue may be a remaining signal 587 from tumorigenesis. 588
Whether cancer related overexpression of the two miRNAs described here is merely 589 consequences of other molecular mechanisms in cancer cells or whether the two miRNAs 590 may be involved in tumorigenesis, but not subsequent cancer progression, remains 591
unknown. 592 593 594
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